Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.
As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.
Publication Alerts
Subscribe to receive alerts once a paper has been published by Oncotarget.
On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control.
This malicious action will be reported to the FBI.
On August 25, 2022, the Office of Science and Technology Policy announced a new government policy legislating the immediate public release of all United States-funded research publications by 2025. Learn more here and here.
On May 23, 2023, the Council of the European Union adopted conclusions on high-quality, transparent, open, trustworthy, and equitable scholarly publishing. The Council calls for immediate and unrestricted open access to publishing research involving public funds. Learn more.
As highlighted in the abstract of this editorial, the emergence of immunotherapy (IO), and more recently, intratumoral IO, offers a novel approach to cancer treatment. This method enhances immune responses, allows for combination therapies, and helps reduce systemic adverse events. These techniques aim to transform the therapeutic paradigm of oncology care, highlighting the limitations of traditional assessment methods and the need for innovative approaches. Artificial intelligence (AI), along with machine learning algorithms and radiomics, offers promising solutions by analyzing complex imaging data to identify biomarkers. These advancements help refine diagnoses, guide interventions, predict treatment responses, and adapt therapeutic strategies.
“We discuss their potential to enhance the survival and quality of life of patients treated with intratumoral IO by improving treatment effectiveness and minimizing side effects, potentially reshaping practice guidelines.”
The authors also identify areas for future research and review clinical trials to confirm the efficacy of such promising approaches.
Correspondence to: Laurent Dercle - [email protected] Keywords: cancer, interventional radiology, artificial intelligence, radiology, radiomics, intratumoral immunotherapy, Precision Medicine
Click hereto sign up for freeAltmetric alerts about this article.
About Oncotarget: Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Oncotarget is indexed and archived byPubMed/Medline,PubMed Central,Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).
To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media:
